To date, only two replicated loci, LPA and PALMD, have been identified as causal genes for calcific aortic valve stenosis (CAVS) using genome-wide and transcriptome-wide association study (TWAS). To identify additional susceptibility genes for CAVS, we performed a GWAS meta-analysis totaling 5,115 cases and 354,072 controls of European descent. Four loci achieved genome-wide significance, including two new loci: IL6 (interleukin 6) on 7p15.3 and ALPL (alkaline phosphatase) on 1p36.12. A TWAS integrating an eQTL study of 233 human aortic valves identified NAV1 (neuron navigator 1) on 1q32.1 as a new candidate causal gene. The CAVS risk alleles were associated with higher mRNA expression of NAV1 in valve tissues.
Main text
Calcific aortic valve stenosis (CAVS) is characterized by progressive thickening and calcification of the aortic valve leaflets causing blood flow obstruction, heart failure and death 1 .
Symptomatic patients with CAVS are treated by surgical aortic valve replacement. CAVS is the second most frequent indication for cardiac surgery after coronary artery bypass grafting 2 . No medical treatment is available and conventional cardiovascular drugs tested in clinical trials of CAVS have failed to slow the progression of the disease and/or reduce associated adverse events 1, [3] [4] [5] . The pathophysiological mechanisms associated with the development of CAVS remain elusive. Previous epidemiological studies on CAVS described familial patterns compatible with genetic inheritance and indicated that genetics contribute more than environmental factors to disease susceptibility 6, 7 . Unbiased genomic approaches are just starting to elucidate the genetic determinants of CAVS [8] [9] [10] . To date, only three susceptibility loci have been associated with aortic valve calcification and/or stenosis in recent GWAS/TWAS [8] [9] [10] . The first GWAS identified LPA 9 , which encodes for lipoprotein(a), and our recent efforts using a TWAS approach identified PALMD as a candidate target gene for CAVS 8 . Another independent group reported associations at the PALMD and TEX41 loci with aortic valve stenosis and bicuspid aortic valve 10 . The discovery of new loci to understand the genetic architecture of CAVS will provide invaluable information about key molecular processes and could open novel therapeutic avenues.
We undertook a GWAS meta-analysis including four cohorts: QUEBEC-CAVS, CAVS-France-1, CAVS-France-2 and UK Biobank (Online Methods). A total of 5,115 cases and 354,072 controls of European ancestry were included after quality control filters were applied ( Table 1) .
We used the Haplotype Reference Consortium 11 as reference to impute common variants. We performed a fixed-effects meta-analysis using the summary statistics for the association between ~ 8 million SNPs and CAVS risk in each cohort. The quantile-quantile plot indicated no inflation of observed test statistics (Supplementary Fig. 1) . Four loci reached genome-wide significance (PGWAS<5x10 -8 ), including two previously described loci, namely LPA on 6q25.3-q26 and PALMD on 1p21.2 8, 9 (Fig. 1) , and two new loci: the interleukin 6 (IL6) gene on 7p15.3 (rs2069832, P=1.1x10 -8 ) and the alkaline phosphatase (ALPL) gene (rs12141569, P=3.9x10 -8 ) on 1p36.12 ( Fig. 1 & Fig. 2) . The lead SNPs for all loci with PGWAS<1x10 -5 are indicated in Supplementary Table 1 .
We have then integrated the summary statistics from the four-cohort meta-analysis with our valve eQTL dataset (n=233) to perform a new TWAS on CAVS. PALMD, identified in our previous TWAS 8 , is strongly associated with CAVS (PTWAS=3.6x10 -17 ; Fig. 3a ). After correction for the number of genes with significant cis-heritability to calculate expression weights in the valve eQTL dataset (n=11,834), one additional gene reached the significance threshold (PTWAS<4.2x10 -6 ), namely neuron navigator 1 (NAV1) (PTWAS=2.0x10 -6 ). NAV1 is located on chromosome 1q32.1; the lead GWAS SNP is rs665770, located in intron 3 (PGWAS=1.5x10 -6 ) ( Supplementary Fig. 2 and Fig. 3b ). It is also the lead valve eQTL-SNP (PeQTL=5.9x10 -11 ). The risk allele for CAVS ("A") is associated with higher mRNA expression levels of NAV1 in valve tissues ( Fig. 3c) . Moreover, Bayesian colocalization test 12 indicated a high probability of shared GWAS and NAV1 eQTL signals (PP4=98.3%). Finally, the CAVS risk alleles were consistently associated with increased expression of NAV1 in aortic valve tissues ( Fig. 3d) . Together, these results suggest that this locus confers susceptibility through higher expression of NAV1 in the aortic valve.
Overall, three new CAVS risk loci were discovered in this study: IL6, ALPL, and NAV1, among which only NAV1 had significant eQTL in our aortic valve dataset. A series of post-GWAS analyses were then carried out to determine the variants most likely to be functional and gain further insight about these new CAVS loci. We also sought to identify pathways, cell or tissue types driving the genetic risk of CAVS and assessed the genetic correlation of CAVS with other traits/diseases.
Fine-mapping to localize the potential causal variants at CAVS loci was performed using PAINTOR 13 with the following annotations: conservation score, fetal DNase I hypersensitive sites (DHS), promoter region and H3K4me1 peaks. For our previously reported PALMD locus, the lead GWAS SNP, rs6702619, provides a posterior probability for causality (PPC) of 0.98.
For the IL6 locus, rs1800795 achieved a similarly strong PPC of 0.96. This SNP is located <1 kb from the lead SNP rs2069832 (LD r 2 =0.97 in 1000 Genomes Europeans). For the ALPL locus, the index SNP, rs12141569, has the top PPC of 0.55, but a second plausible functional variant was identified (rs7547128 with a PPC of 0.21). Finally, three SNPs were prioritized for the NAV1 locus, including rs7535989, rs665770 (GWAS lead SNP), and rs665834 with PPCs of 0.54, 0.15, and 0.06, respectively. Predicted effects on chromatin features using the DeepSEA 14 algorithm for the lead SNPs and variants identified using PAINTOR at the three new CAVS loci are available in Supplementary Table 2 .
CAVS-associated variants were evaluated for eQTL in GTEx 15 . rs2069832-IL6 is a strong eQTL in many tissues (adipose tissues, arteries, breast, esophagus, heart, lung, and others) for the IL6 RNA antisense (LOC541472) (Supplementary Fig. 3 ). The direction of effect is consistent across all tissues, i.e. higher expression corresponds to higher risk of CAVS. Other eQTLs of note in GTEx include rs12141569-ALPL in fibroblasts (PeQTL=1.1x10 -7 ) and rs665770-NAV1 in heart atrial appendage (PeQTL=1.9x10 -8 ). The lead SNPs at the three new loci were further investigated using a phenome-wide association study (PheWAS) in 353,378 individuals of European ancestry from the UK Biobank, testing a total of 832 curated phenotypes. The IL6 variant rs2069832 was strongly associated with eosinophil count (P=7.9x10 -24 ) and to a lower extent with leukocyte, lymphocyte and neutrophil counts, asthma, systolic blood pressure, and carotid artery procedures (Fig. 4a) . The CAVS risk allele was associated with higher eosinophil count, systolic blood pressure and carotid artery procedures, but surprisingly lower risk of asthma. For ALPL, no phenotype was associated with rs12141569 after correction for multiple testing, but a positive nominal association was observed between the CAVS risk allele and bone mineral density (P=4.7x10 -4 , Fig. 4b ). For NAV1, the CAVS risk allele for rs665770 was associated with lower diastolic blood pressure (P=6.5x10 -10 ) as well as higher risk of carotid artery stenosis (P=7.4x10 -8 ) and carotid artery procedures (P=1.7x10 -5 ) ( Fig. 4c) . Bayesian colocalization 12 demonstrated shared GWAS signals between our CAVS meta-analysis, carotid stenosis (PP4=98.5%) and carotid procedures (PP4=97%) in UK Biobank (Supplementary Fig.   4 ).
Although the exact pathophysiological mechanisms remain to be elucidated, the three identified genes can be functionally linked to CAVS. Interleukin 6 has been identified previously as a strong promoter of valve interstitial cells mineralization 16 . The RNA antisense modulated in various tissues by our lead variant is strongly upregulated in monocytes during fungal infection 17 and was shown to induce IL6 expression in glioma cells by causing the enrichment of histone H3 acetylated at lysine 27 (H3K27Ac) of the IL6 promoter 18 . The ALPL gene codes for tissue nonspecific alkaline phosphatase (ALPL, also called TNAP), a crucial enzyme involved in the mineralization process 19 , and was found to be enriched in calcified aortic valves as compared to non-calcified valves 20 . Although our lead variant was not associated with blood alkaline phosphatase levels in previous GWAS [21] [22] [23] , an effect on ALPL activity is possible, as suggested from our PheWAS analysis as well as a recent GWAS showing an even stronger association of rs12141569 with bone mineral density (P=9.9x10 -9 ) 24 . NAV1 is strongly expressed in the human heart 25 , as well as in the aorta (GTEx Portal); our lead SNP shows eQTLs in aortic valve tissue which colocalizes with CAVS risk as well as with carotid stenosis in UK Biobank. This locus was also associated with diastolic blood pressure and pulse pressure in previous GWAS 26, 27 , pointing to an effect on blood vessel integrity. Arterial blood pressure and the aortic root morphology have been previously identified as risk factors for CAVS and its progression over time 28, 29 .
Tissue and gene-set enrichment were performed with DEPICT 30 using SNPs nominally associated with CAVS (PGWAS<1x10 -5 ). At the tissue level, enrichments with nominal PDEPICT<0.05 were observed for arteries, veins and blood vessels, but none were significant at FDR<5%. Similarly, no gene sets were significantly enriched at FDR<5%. Top nominal pathways of interest include increased compact bone thickness, increased heart weight, disorganized myocardium and increased systemic arterial diastolic blood pressure ( Supplementary Table 3 ). We also tested enrichment of CAVS-associated loci (PGWAS<1x10 -5 ) in DHS in cell lines and tissues from ENCODE and the Epigenome Roadmap Project using FORGE 31 and GARFIELD 32 . Leading tissues were heart, blood vessels and fibroblast, but no overlap reached statistical significance ( Supplementary Fig. 5 ). LD score regression 33 was then used to test genetic correlation with other traits and diseases (Supplementary Table 3 ). We discovered significant genetic correlation with CAD, myocardial infarction, diastolic and systolic blood pressure, body mass index, type 2 diabetes and large-artery stroke ( Table 2 ).
In conclusion, we describe three new risk loci for CAVS (IL6, ALPL and NAV1) implicating inflammation, mineralization and blood vessel integrity in the disease pathogenesis. These genes provide key insights into the etiology of CAVS and constitute novel targets for the development of therapeutic agents. Our association results at the genome-wide scale show genetic correlation with cardiovascular disease and cardiovascular risk factors, supporting a shared genetic etiology.
Methods

Study cohorts
QUEBEC-CAVS
A complete description of the cohort has already been published 8 Blood samples were collected and DNA was extracted from frozen buffy coat. Whole-genome genotyping was performed using the Illumina HumanOmniExpress BeadChip. Standard genotyping quality control (QC) procedures were performed 8 . After the QC filters, 1,009 cases and 1,017 controls were available for subsequent analyses. Genotypes were imputed with the Michigan Imputation Server 34 using the Haplotype Reference Consortium version 1 (HRC.r1-1) data 11 as reference set.
Genetic association tests were performed using additive logistic regression models based on expected genotype counts (dosages) as implemented in the software SNPTEST v2.5.2 35 , adjusting for age, sex, and the first 10 ancestry-based principal components.
French Datasets
A large cohort of "isolated" CAVS cases has been constituted by l'institut du thorax in Nantes. A Doppler-echocardiography and blood sampling were carried out at the time of enrollment.
Patients with severe renal failure, history of rheumatic disease or chest radiation were excluded.
So far, 1,663 severe CAVS cases (including patients with tricuspid or bicuspid valves), have been recruited from 2001 to 2017 thanks to a collaboration between Nantes, Rennes and Angers University Hospitals. Most of them have been referred to surgery after enrollment and valve tissue was collected in a subset of patients. The study was approved by the local ethics committee and all patients signed an informed consent for the purpose of genetic studies.
Coronary artery disease was defined as previously described in the QUEBEC-CAVS cohort.
In parallel, the Cardiovascular department in Bichat university Hospital in Paris has recruited 1,500 patients with CAVS, including patients with tricuspid or bicuspid valves (GENERAC and COFRASA projects). All patients were prospectively enrolled and fully phenotyped. Blood samples and valve tissues were collected (DNA, blood and tissue bank stored at the level of our Center of Biological Resources). 36, 37 is an epidemiological cohort used here as a control general population. PREGO (Population de Référence du Grand Ouest) is a set of 5,707 healthy persons selected through the Blood Donor Service, originating from Western France, as a resource dedicated to provide a regional reference population of Western France for national and international research projects in the field of evolution, population and medical genetics. CAVS status was not available in D.E.S.I.R. and PREGO because of the lack of echocardiography data in this cohort.
The patients were genotyped in two waves:
CAVS-France-1
A set of 1,329 patients with CAVS from the institut du thorax biobank were genotyped using Axiom Genome-Wide CEU-1 array (Affymetrix, Inc). We used a general population as controls.
A subset of 901 individuals came from the D.E.S.I.R. population and 466 from the PREGO population.
We applied quality control procedures to filter markers (genotyping rate and heterozygosity) and individuals (relatedness and demographic stratification). The ancestry of participants was assessed using a multi-dimensional scaling technique implemented in PLINK 38 . Multi-dimensional scaling method was applied on the Identity-By-State matrix using cases and controls together with all 1000G populations and all non-Finnish European populations. We excluded outliers on the first two components using an expectation-maximization (EM)-fitted Gaussian mixture clustering method implemented in the R package M-CLUST 39 , assuming one cluster and noise. Outlier position was initialized using a nearest-neighbour-based classification (NNclust in R package PrabClus) 40 .
After quality control, we kept 1,261 CAVS patients (18.5% had a bicuspid valve) and 1,305 controls (865 individuals from the D.E.S.I.R. population and 440 from the PREGO population).
A final list of 350,488 SNPs were used for imputation (138,199 SNPs were removed for genotyping rate or low MAF or HWE deviation and 1,095 SNPs removed due to technical differences between genotyping plates).
CAVS-France-2
The French CAVS-France-2 dataset was genotyped using Axiom Genome-Wide PMRA array (Affymetrix, Inc). The dataset is composed of a set of 1,478 patients recruited at the Hôpital Bichat, 319 patients from the institut du thorax biobank and 2,828 controls from the PREGO population.
We applied the same quality control procedures and selection on individuals as for the CAVS- Imputation for both France cohorts was performed using the Michigan Imputation Server 34 with the Haplotype Reference Consortium version 1 (HRC.r1-1) data 11 as reference set.
Genetic association tests were performed using additive logistic regression models based on expected genotype counts (dosages) as implemented in the software SNPTEST v2.5.2 35 , adjusting for the first 5 ancestry-based principal components as well as the components associated with the disease among the fifth to tenth principal components. Participants with a history of rheumatic fever or rheumatic heart disease as determined by ICD10 codes I00-I02 and I05-I09 were excluded from the CAVS group. We included all other participants in the control group, except for those with OPCS-4 codes K26 or K30.2 or a selfreported diagnosis of CAVS, which were excluded from the analysis. Samples were genotyped with the Affymetrix UK BiLEVE Axiom array or the Affymetrix UK Biobank Axiom Array.
UK Biobank
Phasing and imputation were performed centrally using the Haplotype Reference Consortium (HRC) reference panel 11 . Samples with call rate <95%, outlier heterozygosity rate, gender mismatch, non-white British ancestry, related samples (second degree or closer), samples with excess third-degree relatives (>10), or not used for relatedness calculation were excluded.
Variants not on both arrays, which failed QC in more than one batch, with call rate <95% or with minor allele frequency (MAF) <0.01 were excluded. To estimate the association of each variant with CAVS, we performed linear regression following an additive model using BGENIE (BioRxiv: https://www.biorxiv.org/content/early/2017/07/20/166298), with adjustment for age, sex and the first 20 ancestry-based principal components. This program was developed to perform efficient GWAS in large populations and was specifically written for the analysis of the UK Biobank dataset.
Meta-analysis
The genomic inflation factors in the four cohorts were 1.029 (QUEBEC-CAVS), 1.031 (CAVS-France-1), 1.050 (CAVS-France-2), and 1.021 (UK Biobank). Genomic correction was applied to each cohort. Variants with an r 2 value of ≤0.3 or MAF <0.01 were removed in each cohort.
We performed a fixed-effects sample size-weighted meta-analysis as implemented in METAL 42 .
The effective sample size was calculated as 4/(1/Ncases + 1/Ncontrols) to account for imbalance in the number of cases and controls in each cohort. The weights were proportional to the squareroot of the effective sample size. Genomic correction was applied to the results of the metaanalysis (lambda =1.022). For variants associated with CAVS below a P value threshold of 1x10 -5 in the sample size weighted meta-analysis, we used logistic regression models in UK Biobank, as implemented in the software SNPTEST v2.5.2 35 , to obtain effect size estimates. Models were based on expected genotype counts (dosages), with adjustment for age, sex, and the first 10 ancestry-based principal components. We then performed the meta-analysis again for these variants using a fixed-effects inverse-variance weighted method. Heterogeneity was evaluated using Cochran's Q-test as implemented in METAL 42 . The genome-wide significant P value cutoff was set to 5x10 −8 .
Transcriptome-wide association study (TWAS)
The TWAS was performed using FUSION 43 . Our aortic valve eQTL dataset, which includes 233 individuals, was used as reference 8 . Gene expression weights were calculated using prediction models implemented in FUSION. This includes top1 (i.e. the single most significant valve eQTL-SNP as the predictor), LASSO regression, and enet (elastic net regression). SNP data located 500 kb on both sides of the probes were used to obtain expression weights. All probes that passed QC in the valve eQTL were evaluated (n=45,699). There were 11,384 genes with significant cis-heritability (P<0.01) to calculate expression weights. Expression weights were then combined with summary-level results from the meta-analysis to estimate association statistics between gene expression and CAVS. Genome-wide significant TWAS genes were considered at PTWAS<4.2x10 -6 (Bonferroni =0.05/11,384).
Post-GWAS analyses
Fine-mapping to identify causal variants
We used Probabilistic Annotation INTegratOR (PAINTOR) 13 to identify candidate causal variants. This program uses a probabilistic framework to integrate LD information, P value distribution in significant loci and functional annotations. We used all SNPs located within 500 kb of the genome-wide significant loci (LPA, PALMD, ALPL, IL6 and NAV1) and with a P value <0.01 for association with CAVS in the GWAS meta-analysis. LD structure was obtained from the 1000 Genomes European reference set. As described previously 44 , we used genetic annotations that were not cell-type specific. The recommended number of annotations to use in PAINTOR is 3 to 5. After determining the significance of each annotation, we selected the following 4 annotations to optimize the model: conservation score, fetal DNase I hypersensitive sites, promoter region and H3K4me1 peaks. Additional annotations did not increase the modelfit or were highly correlated with the 4 selected annotations. We used a model allowing for 1 causal variant.
Investigation of transcriptomic and epigenetic effects
We looked for eQTL associations for the lead SNPs at the newly identified loci in the Genotype-Tissue Expression (GTEx-V7) project data 15 . This resource provides eQTL data from 48 tissues (620 individuals).
We looked at the effects of the variants with suggestive association with CAVS in the metaanalysis (P value <1x10 -5 ) on transcription factor binding and chromatin marks in 149 cell lines from ENCODE and the Roadmap Epigenomics project using DeepSEA 14 .
Colocalization
When the newly identified loci had significant eQTL associations, we tested for colocalization between the CAVS risk association and the aortic valve or other tissues eQTL association. We used the COLOC package in R to perform Bayesian colocalization analyses 12 . COLOC tests for five hypotheses: H0, no eQTL and no GWAS association; H1, association with eQTL, but no GWAS; H2, association with GWAS, but no eQTL; H3, eQTL and GWAS associations, but independent signals; and H4, shared eQTL and GWAS associations. In practice, a high posterior probability of H4 (PP4>75%) indicates colocalization.
Phenome-wide association studies
We verified the association between the lead variant in the two new genome-wide significant loci (ALPL and IL6) as well as the new locus identified with TWAS (NAV1) and a wide range of phenotypes in the UK Biobank. We curated 832 phenotypes from anthropometric traits, health questionnaires, ICD10 diagnostic codes, OPCS-4 procedure codes, imaging data and laboratory markers. Phenotypes were grouped in the following categories: anthropometric, cardiovascular, dermatologic, digestive, endocrine, genitourinary, hematologic, infectious, lifestyle, musculoskeletal, neoplasms, neurological, pregnancy, psychiatric, respiratory, sense organs and others. Continuous variables were examined individually to exclude outlier values and quantile normalization was applied. For each phenotype, an additive logistic (binary phenotype) or linear regression (continuous phenotype) test was performed in 353,378 unrelated individuals of White-British ancestry, adjusting for age, sex and the first 10 ancestry-based principal components using SNPTEST v2.5.2 35 . Results for each phenotype were plotted using the PheWAS R package. A significance threshold of P=6.0x10 -5 (0.05/832) was applied to correct for multiple testing. We used the colocalization procedure described above to test for shared causal association between CAVS and other phenotypes identified in the PheWAS.
Pathway analyses and tissue enrichment
We used data-driven expression-prioritized integration for complex traits (DEPICT) 30 to identify over-represented biological pathways and enrichment in tissues among the variants with suggestive association with CAVS (P<1x10 -5 ). We selected independent variants by applying LD pruning based on European individuals from the 1000 Genomes using a threshold of r 2 <0.05.
We tested enrichment of CAVS-associated loci (P<1x10 -5 ) in DNase I sensitivity hotspots in cell lines and tissues from ENCODE and the Roadmap Epigenomics project using the Functional element Overlap analysis of the Results of Genome Wide Association Study Experiments (FORGE) tool 31 . We used GARFIELD 32 to correlate our GWAS findings with regulatory or functional annotations and find features relevant to a phenotype of interest. Since our GWAS included only European individuals, we used the original files describing the allele frequencies and linkage disequilibrium from the UK10K data provided in the GARFIELD distribution. We also used the annotation and distance to TSS files provided with the GARFIELD release. The annotations included 1,005 features extracted from ENCODE, GENCODE and Roadmap Epigenomics projects, including genic annotations, chromatin states, histone modifications, DNase I hypersensitive sites and transcription factor binding sites, among others, in a number of publicly available cell lines.
Genetic correlation
We performed LD-score regression to estimate the genetic correlation between CAVS and other cardiovascular traits 33, 45 . We used the results of the sample size weighted CAVS GWAS metaanalysis (performed without genomic correction). Summary statistics from GWAS meta-analyses on cardiovascular traits (coronary artery disease, blood pressure, hypertension, blood lipids, type 2 diabetes, body mass index, waist-to-hip ratio, stroke, chronic kidney disease) were obtained from publicly available resources ( Supplementary Table 4 ). For each trait, we removed SNPs located in the major histocompatibility complex region (chr 6; positions 28, 477, 448, 354 GRCh37), SNPs with an extreme effect size (chi 2 statistic >80) and selected a subset of SNPs included in HapMap3 to optimize imputation quality. We used the European LD-score files calculated from 1000 Genomes reference panel provided by the developers. For the blood pressure traits, since both populations included the UK Biobank, we constrained the intercept based on the amount of overlap and correlation between CAVS and the trait evaluated. Analyses were performed using the ldsc program (https://github.com/bulik/ldsc/). A conservative P value threshold of <0.001 was considered significant.
Statistical analysis
Statistical analyses were performed with R version 3.2.3 unless otherwise specified. Two-sided P values below 0.05 were considered significant unless otherwise specified.
We would like to specially thank the team of the Centre d'Investigation Clinique (Xavier Duval), The PREGO bio-collection is part of the VaCaRMe program founded by the French Regional Council of Pays-de-la-Loire (RFI VaCaRMe). The authors wish to thank the Fondation Genavie for its financial support. We would like to specially thank Stephanie Chatel for all her contribution to constitute this bio-collection. We thank the Etablissement Français du Sang and the Centre de Ressources Biologiques of CHU de Nantes, for its support. We thank our numerous collaborators for the recruitment of blood donors, and all participating individuals. The extent of linkage disequilibrium (LD; r 2 values) for all SNPs with rs665770 is indicated by colors. The location of genes in this locus is illustrated at the bottom. (c) Boxplots of gene expression levels in the valves according to the three genotype groups for SNP rs665770. The yaxis shows the mRNA expression levels. The x-axis represents the three genotype groups for rs665770 with the number of individuals in parenthesis. Expression data for the NAV1 probe was not available for 3 individuals (n=230). The risk allele identified in our GWAS meta-analysis is shown in red. Box boundaries, whiskers and center marks in boxplots represent the first and third quartiles, the most extreme data point which is no more than 1.5 times the interquartile range, and the median, respectively. The black bar and the left y axis indicate the variance in 
